C4 Therapeutics Net Income
| CCCC Stock | USD 1.71 0.18 9.52% |
As of the 6th of February, C4 Therapeutics owns the Market Risk Adjusted Performance of (0.34), information ratio of (0.13), and Variance of 20.92. C4 Therapeutics technical analysis gives you the methodology to make use of past data patterns to determine a pattern that approximates the direction of the entity's future prices.
C4 Therapeutics Total Revenue |
|
Gross Profit | Market Capitalization | Enterprise Value Revenue 2.1543 | Revenue | Earnings Share (1.57) |
| Last Reported | Projected for Next Year | ||
| Net Loss | -94.8 M | -99.5 M | |
| Net Loss | -115.4 M | -109.6 M | |
| Net Loss | -94.8 M | -99.5 M | |
| Net Loss | (1.75) | (1.83) | |
| Net Income Per E B T | 1.15 | 1.11 |
CCCC | Net Income | Build AI portfolio with CCCC Stock |
Analyzing C4 Therapeutics's Net Income over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Income has evolved provides context for assessing C4 Therapeutics's current valuation and future prospects.
Latest C4 Therapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of C4 Therapeutics over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in C4 Therapeutics financial statement analysis. It represents the amount of money remaining after all of C4 Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is C4 Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in C4 Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (105.32 M) | 10 Years Trend |
|
Net Income |
| Timeline |
CCCC Net Income Regression Statistics
| Arithmetic Mean | (52,118,648) | |
| Coefficient Of Variation | (86.62) | |
| Mean Deviation | 40,669,233 | |
| Median | (15,711,000) | |
| Standard Deviation | 45,144,332 | |
| Sample Variance | 2038T | |
| Range | 116.8M | |
| R-Value | (0.86) | |
| Mean Square Error | 583.7T | |
| R-Squared | 0.73 | |
| Significance | 0.000012 | |
| Slope | (7,646,053) | |
| Total Sum of Squares | 32608.2T |
CCCC Net Income History
Other Fundumenentals of C4 Therapeutics
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
C4 Therapeutics Net Income component correlations
CCCC Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for C4 Therapeutics is extremely important. It helps to project a fair market value of CCCC Stock properly, considering its historical fundamentals such as Net Income. Since C4 Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of C4 Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of C4 Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Will Biotechnology sector continue expanding? Could CCCC diversify its offerings? Factors like these will boost the valuation of C4 Therapeutics. Projected growth potential of CCCC fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every C4 Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (1.57) | Revenue Per Share | Quarterly Revenue Growth (0.27) | Return On Assets | Return On Equity |
Understanding C4 Therapeutics requires distinguishing between market price and book value, where the latter reflects CCCC's accounting equity. The concept of intrinsic value - what C4 Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push C4 Therapeutics' price substantially above or below its fundamental value.
It's important to distinguish between C4 Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding C4 Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, C4 Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
C4 Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to C4 Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of C4 Therapeutics.
| 11/08/2025 |
| 02/06/2026 |
If you would invest 0.00 in C4 Therapeutics on November 8, 2025 and sell it all today you would earn a total of 0.00 from holding C4 Therapeutics or generate 0.0% return on investment in C4 Therapeutics over 90 days. C4 Therapeutics is related to or competes with Insight Molecular, Sangamo Therapeutics, Cybin, Molecular Partners, Codexis, PepGen, and Armata Pharmaceuticals. C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade dise... More
C4 Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure C4 Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess C4 Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.13) | |||
| Maximum Drawdown | 24.93 | |||
| Value At Risk | (7.83) | |||
| Potential Upside | 8.06 |
C4 Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for C4 Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as C4 Therapeutics' standard deviation. In reality, there are many statistical measures that can use C4 Therapeutics historical prices to predict the future C4 Therapeutics' volatility.| Risk Adjusted Performance | (0.08) | |||
| Jensen Alpha | (0.60) | |||
| Total Risk Alpha | (0.76) | |||
| Treynor Ratio | (0.35) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of C4 Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
C4 Therapeutics February 6, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.08) | |||
| Market Risk Adjusted Performance | (0.34) | |||
| Mean Deviation | 3.4 | |||
| Coefficient Of Variation | (852.02) | |||
| Standard Deviation | 4.57 | |||
| Variance | 20.92 | |||
| Information Ratio | (0.13) | |||
| Jensen Alpha | (0.60) | |||
| Total Risk Alpha | (0.76) | |||
| Treynor Ratio | (0.35) | |||
| Maximum Drawdown | 24.93 | |||
| Value At Risk | (7.83) | |||
| Potential Upside | 8.06 | |||
| Skewness | 0.7044 | |||
| Kurtosis | 1.65 |
C4 Therapeutics Backtested Returns
C4 Therapeutics retains Efficiency (Sharpe Ratio) of -0.0916, which signifies that the company had a -0.0916 % return per unit of price deviation over the last 3 months. C4 Therapeutics exposes twenty-two different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm C4 Therapeutics' Variance of 20.92, information ratio of (0.13), and Market Risk Adjusted Performance of (0.34) to double-check the risk estimate we provide. The firm owns a Beta (Systematic Risk) of 1.57, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, C4 Therapeutics will likely underperform. At this point, C4 Therapeutics has a negative expected return of -0.42%. Please make sure to confirm C4 Therapeutics' mean deviation, jensen alpha, potential upside, as well as the relationship between the standard deviation and treynor ratio , to decide if C4 Therapeutics performance from the past will be repeated sooner or later.
Auto-correlation | 0.69 |
Good predictability
C4 Therapeutics has good predictability. Overlapping area represents the amount of predictability between C4 Therapeutics time series from 8th of November 2025 to 23rd of December 2025 and 23rd of December 2025 to 6th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of C4 Therapeutics price movement. The serial correlation of 0.69 indicates that around 69.0% of current C4 Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.69 | |
| Spearman Rank Test | 0.67 | |
| Residual Average | 0.0 | |
| Price Variance | 0.02 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
CCCC Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, C4 Therapeutics reported net income of (105.32 Million). This is 130.86% lower than that of the Biotechnology sector and 250.35% lower than that of the Health Care industry. The net income for all United States stocks is 118.44% higher than that of the company.
CCCC Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses C4 Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of C4 Therapeutics could also be used in its relative valuation, which is a method of valuing C4 Therapeutics by comparing valuation metrics of similar companies.C4 Therapeutics is currently under evaluation in net income category among its peers.
C4 Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of C4 Therapeutics from analyzing C4 Therapeutics' financial statements. These drivers represent accounts that assess C4 Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of C4 Therapeutics' important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 1.4B | 1.5B | 288.3M | 280.5M | 322.5M | 306.4M | |
| Enterprise Value | 1.3B | 1.4B | 345.7M | 224.9M | 258.6M | 245.7M |
C4 Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in C4 Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of C4 Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing C4 Therapeutics' value.| Shares | Goldman Sachs Group Inc | 2025-06-30 | 880.3 K | Two Sigma Advisers, Llc | 2025-06-30 | 811.4 K | Geode Capital Management, Llc | 2025-06-30 | 745.1 K | Two Sigma Investments Llc | 2025-06-30 | 683.6 K | Ubs Group Ag | 2025-06-30 | 572 K | Jane Street Group Llc | 2025-06-30 | 492.6 K | Jacobs Levy Equity Management, Inc. | 2025-06-30 | 441.7 K | Dimensional Fund Advisors, Inc. | 2025-06-30 | 431.9 K | Aqr Capital Management Llc | 2025-06-30 | 383.8 K | Wasatch Advisors Lp | 2025-06-30 | 7.4 M | Soleus Capital Management, L.p. | 2025-06-30 | 7 M |
CCCC Fundamentals
| Return On Equity | -0.6 | ||||
| Return On Asset | -0.23 | ||||
| Operating Margin | (2.11) % | ||||
| Current Valuation | 51.78 M | ||||
| Shares Outstanding | 96.91 M | ||||
| Shares Owned By Insiders | 7.19 % | ||||
| Shares Owned By Institutions | 73.79 % | ||||
| Number Of Shares Shorted | 7.38 M | ||||
| Price To Book | 1.26 X | ||||
| Price To Sales | 6.08 X | ||||
| Revenue | 35.58 M | ||||
| Gross Profit | (81.66 M) | ||||
| EBITDA | (103.37 M) | ||||
| Net Income | (105.32 M) | ||||
| Cash And Equivalents | 307.78 M | ||||
| Cash Per Share | 6.29 X | ||||
| Total Debt | 65.76 M | ||||
| Debt To Equity | 0.25 % | ||||
| Current Ratio | 6.90 X | ||||
| Book Value Per Share | 2.08 X | ||||
| Cash Flow From Operations | (65.16 M) | ||||
| Short Ratio | 4.40 X | ||||
| Earnings Per Share | (1.57) X | ||||
| Price To Earnings To Growth | 0.07 X | ||||
| Target Price | 9.86 | ||||
| Number Of Employees | 110 | ||||
| Beta | 2.95 | ||||
| Market Capitalization | 183.17 M | ||||
| Total Asset | 349.6 M | ||||
| Retained Earnings | (633.7 M) | ||||
| Working Capital | 212.59 M | ||||
| Current Asset | 1 K | ||||
| Current Liabilities | 49 K | ||||
| Net Asset | 349.6 M |
About C4 Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze C4 Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of C4 Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of C4 Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether C4 Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of C4 Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of C4 Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on C4 Therapeutics Stock:Check out For information on how to trade CCCC Stock refer to our How to Trade CCCC Stock guide.You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Will Biotechnology sector continue expanding? Could CCCC diversify its offerings? Factors like these will boost the valuation of C4 Therapeutics. Projected growth potential of CCCC fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every C4 Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (1.57) | Revenue Per Share | Quarterly Revenue Growth (0.27) | Return On Assets | Return On Equity |
Understanding C4 Therapeutics requires distinguishing between market price and book value, where the latter reflects CCCC's accounting equity. The concept of intrinsic value - what C4 Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push C4 Therapeutics' price substantially above or below its fundamental value.
It's important to distinguish between C4 Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding C4 Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, C4 Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.